Table 2 Availability of anti-malarial drugs in Burundi (70 outlets), by public and private sector
From: Anti-malarial market and policy surveys in sub-Saharan Africa
| Â | Number of anti-malarial drugs in outlets surveyed (n=243) | Number of anti-malarial drugs in the public sector (n=132) | Number of anti-malarial drugs in the private sector (n=111) |
|---|---|---|---|
Amodiaquine (AQ) | 1 (0.4%) | 0 | 1 (0.9%) |
Artemether+lumefantrine (AR+LUM) | 3 (1.2%) | 0 | 3 (2.7%) |
Artesunate+amodiaquine (AS+AQ) | 61 (25.1%) | 46 (34.8%) | 15 (13.5%) |
Dihydroartemisinin + piperaquine (DHA+PQ) | 1 (0.4%) | 0 | 1 (0.9%) |
Dihydroartemisinin (DHA) | 4 (1.6%) | 0 | 4 (3.6%) |
Halofantrine | 16 (6.6%) | 2 (1.5%) | 14 (12.6%) |
Quinine injection | 54 (22.2%) | 29 (22.0%) | 25 (22.5%) |
Quinine tablets | 103 (42.4%) | 55 (41.7%) | 48 (43.2%) |